Distribución comercial

Bienvenido/a a la página de inicio de Distribución comercial en Law-Now.

En esta página encontrarás todos los artículos y publicaciones de Distribución comercial escritos por expertos de CMS en esta área del derecho.

Para mantenerte actualizado/a con las últimas novedades, guarda esta página en tu dispositivo móvil o regístrate para recibir alertas electrónicas.

Artículos Recientes

  •  
    14.03.2023
    China

    Chi­na has ac­ce­ded to the Ha­gue Co­n­ve­n­tion of 5 Oc­to­ber 1961 Abo­li­shi­ng the Re­qui­re­me­nt of Le­ga­li­sa­tion for Fo­rei­gn Pu­b­lic Do­cu­me­n­ts

    On 8 March 2023, the People's Republic of China (the "PRC") has (finally!) acceded to the Hague Convention of 5 October 1961 Abolishing the Requirement of Legalisation for Foreign Public Documents (the "Convention").The Convention between the PRC, as the acceding state, and other member states (which will not have raised an objection; see below) will enter into force as of 7 November 2023.This constitutes a long-awaited and very positive development.Please click here to read the full article.
    Leer más
  •  
    21.02.2023
    Europe

    VBER and Ve­r­ti­cal Gui­de­li­nes lea­ve que­s­tion open on what re­s­t­ri­c­tio­ns are pe­r­mi­s­si­b­le in In­te­r­net sa­les

    Article 4 lit. e) VBER, newly introduced with the 2022 reform of the VBER, regulates a hardcore restriction for all forms of distribution that is specifically geared to Internet commerce, and is now central for the evaluation of by object restrictions on Internet commerce. The requirements are explicitly related to Internet commerce and form a uniform standard of review that is in principle free of contradictions. Together with the Internet-related explanations in the European Commission's Vertical Guidelines, this leads to an increase in legal certainty for the companies concerned. However, the...
    Leer más
  •  
    21.02.2023
    Europe

    Su­n­ri­se pe­riod of the Uni­fied Pa­te­nt Court to be­gin 1 Ma­r­ch

    After the final version of the UPC Rules of Procedure had been adopted and the judges of the UPC had been selected and appointed, the start of the Sunrise Period, originally planned for 1 January 2023, was postponed to 1 March 2023.Reasons for the postponement of the start of the Sunrise PeriodAccording to an "Implementation Roadmap" published on 6 October 2022, the Sunrise Period was originally to start on 1 January 2023 and the UPCA was to enter into force on 1 April 2023. However, this timeline was changed again by a communication of 5 December 2022. According to the new timeline, the Sunrise...
    Leer más
  •  
    06.02.2023
    UAE

    Ba­la­n­ci­ng the boo­ks – new da­wn for co­m­me­r­cial age­n­cies in the UAE

    The most significant update to the UAE commercial agencies regulatory regime in over 40 years has been enacted under Federal Law No. (3) of 2022 on the Regulation of Commercial Agencies (the “New Agency Law”) which comes into force on 15 June 2023. The New Agency Law entirely replaces Federal Law No. (18) of 1981 on the Regulation of Commercial Agencies (the “Old Agency Law”). The New Agency Law still retains a presumption of exclusivity in favour of a registered agent, however it reforms many of the main risks that have troubled foreign principals for many years, enabling...
    Leer más
  •  
    24.01.2023
    Suiza

    Pri­ci­ng of Me­di­ci­nes in Swi­t­ze­r­la­nd | Th­ree-yea­r­ly pri­ce re­view: What are the mo­st im­po­r­ta­nt cha­n­ges for 2023?

    DE GB
    The Federal Office of Public Health (FOPH) reviews the price of every medicinal product that is reimbursed under the statutory health insurance in Switzerland once every three years. These products are included in the list of pharmaceutical specialities (SL). However, the modalities of the review are often controversial and recent case-law requires periodic adjustments. This is no different for the 2023 review. While no fundamental changes are to be expected with regard to the review of the prices of medicinal products that are reimbursed by the mandatory healthcare insurance in Switzerland, there...
    Leer más
  •  
    18.01.2023
    Suiza

    In-vi­t­ro-Dia­g­no­s­ti­ka: Au­f­ga­ben und Ha­f­tu­ng des Sch­wei­zer Be­vo­l­l­mä­ch­ti­g­ten

    DE GB
    Ausländische Hersteller von In-vitro Diagnostika müssen einen Schweizer Bevollmächtigten (CH-REP) bezeichnen, um ihre Produkte in der Schweiz in Verkehr zu bringen. Als Stellvertreter des ausländischen Herstellers hat dieser verschiedene Aufgaben und Pflichten zu erfüllen. Namentlich ist er Ansprechpartner für die Schweizer Behörden und haftet mit dem Hersteller solidarisch für Schäden, die durch fehlerhafte Produkte verursacht worden sind. Nachfolgend finden Sie eine Übersicht über die Aufgaben und Pflichten des Schweizer Bevollmächtigten...
    Leer más